Interviews

New research shows T-cell receptor sequencing can reveal immune signatures of precancer and cancer in Lynch syndrome carriers, aiding early detection.

Doris K. Hansen, MD, discusses what she hopes long-term real-world data on CAR T-cell therapy will show in order to better inform treatment of multiple myeloma.

A 940-patient real-world study confirms alectinib outperforms crizotinib in ALK-positive NSCLC, mirroring results from the landmark ALEX trial.

Heather J. Landau, MD, discusses the most exciting outcomes observed in a trial of BCMA-targeted NXC-201 for light chain amyloidosis.

Doris K. Hansen, MD, discusses outcomes from a large retrospective study of patients treated with ciltacabtagene autoleucel for relapsed/refractory multiple myeloma.

During a live event, Prerna Mewawalla, MD, discussed the choice between bispecific antibody therapy and CAR T-cell therapy in myeloma as both therapies have been introduced earlier in sequence.

Lung cancer increasingly hits never-smoking women; learn how biomarker testing, earlier screening, and stronger self-advocacy speed diagnosis and unlock better treatments.

Two new oncologists share raw truths on fellowship loneliness, fear of autonomy, and building networks that make the leap to faculty survivable.

Oral golcadomide with rituximab delivers high responses and manageable safety, enabling outpatient care for relapsed follicular lymphoma.

Golcadomide plus rituximab shows deep, durable responses in relapsed follicular lymphoma, with manageable neutropenia and limited added toxicity.

In an interview, Melody Chang, MBA, RPh, BCOP, explains the work that went into ensuring access to bispecific antibodies across a network of community oncology practices.

Adam Cuker, MD, MS, discusses how the goals of treatment for immune thrombocytopenia have developed beyond managing platelet count.

Peter Voorhees, MD, discusses the cost-benefit question of adding pomalidomide to daratumumab and talquetamab in early relapsed multiple myeloma.

In an interview, Peter Voorhees, MD, discusses why talquetamab is typically sequenced after BCMA-targeting agents and the unique situations where it might be used first.

Virtual behavioral health embedded in community oncology boosts access for Black patients and patients on Medicaid, easing distress and improving quality of life.

Genome sequencing speeds tumor mutation discovery, boosting targeted cancer therapies and cell/gene treatments while raising urgent questions about data ownership, reporting uncertainty, and ethics.

Data link food deserts to metastatic breast cancer mutations and shorter survival, urging oncologists to screen for food insecurity.

Triplet therapy ziftomenib plus venetoclax/azacitidine boosts MRD-negative remissions in relapsed NPM1-mutated AML, hinting at earlier use.

INSIGHT tests if NSCLC super-responders with pathologic complete response can skip adjuvant durvalumab, reducing toxicity without sacrificing survival.

Heather J. Landau, MD, discusses results from a trial of the investigational CAR T-cell therapy NXC-201 in relapsed/refractory AL amyloidosis.

Genetic testing isn’t the finish line—learn how evolving risk models, dense breast guidance, and MCED screening may transform early cancer detection.

SEQUOIA subgroup shows zanubrutinib sustains 64% PFS at 6 years in CLL patients ≥80, with low early discontinuations and manageable safety.

Ziftomenib combinations show promising frontline AML results, expanding trials with chemo and targeted partners; phase 3 aims to shift induction therapy standards worldwide.

KOMET-007 insights show ziftomenib’s manageable toxicity, low QTc risk, and easy oral dosing, supporting long-term AML therapy and maintenance.

Community oncology prepares for routine genetic testing, building workflows, training and follow-up to expand hereditary cancer risk care and reduce disparities.

Heather J. Landau, MD, discussed promising results of CAR T-cell therapy in light chain amyloidosis and the challenge of developing trials for this rare plasma cell disorder.

Ranjit Goudar, MD explains how community oncology practices are expanding hereditary cancer care through genetic testing, workflow redesign, and personalized prevention strategies.

Ziftomenib plus 7+3 in newly diagnosed AML shows manageable safety and 90%+ deep responses with high MRD negativity and encouraging early survival in KOMET-007.

KOMET-007 data spotlight ziftomenib combos in newly diagnosed NPM1/KMT2A AML, detailing dosing, sequencing, and maintenance with 7+3 or aza/ven.

Early phase 2 results suggest 12-cycle pirtobrutinib–obinutuzumab yields high responses in untreated CLL with minimal cardiac effects.